Published in Hepatology on December 01, 2012
A Prospective Multicenter Study of Acute on Chronic Liver Failure in China | NCT02457637
Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2014) 3.38
Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. Dig Dis Sci (2015) 2.03
Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol (2013) 1.68
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology (2015) 1.32
Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology (2014) 1.16
Acute-on-chronic liver failure. Clin Mol Hepatol (2013) 1.03
Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther (2012) 0.99
Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol (2014) 0.99
Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol (2014) 0.95
Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. World J Gastroenterol (2014) 0.94
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology (2016) 0.92
Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis (2013) 0.85
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS One (2015) 0.83
Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther (2013) 0.83
Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol (2016) 0.83
The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology (2016) 0.82
Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. World J Gastroenterol (2015) 0.82
Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. Sci Rep (2015) 0.80
Impact of transjugular intrahepatic portosystemic shunt on post-colectomy complications in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterol Rep (Oxf) (2014) 0.80
Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. Gut (2016) 0.79
Acute-on-chronic liver failure. Clin Liver Dis (2014) 0.79
Defining acute-on-chronic liver failure: East, West or Middle ground? World J Hepatol (2015) 0.79
Understanding infection susceptibility in patients with acute-on-chronic liver failure. Intensive Care Med (2014) 0.78
Hepatosplanchnic circulation in cirrhosis and sepsis. World J Gastroenterol (2015) 0.78
The digestive tract as the origin of systemic inflammation. Crit Care (2016) 0.77
Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. Am J Gastroenterol (2017) 0.77
Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. Clin Transl Gastroenterol (2014) 0.77
Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition. PLoS One (2016) 0.77
Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia. World J Gastroenterol (2015) 0.77
Association between Portal Vein Thrombosis and Survival in Non-Liver-Transplant Patients with Liver Cirrhosis: A Systematic Review of the Literature. Gastroenterol Res Pract (2015) 0.77
Clostridium difficile infection in patients with liver disease: a review. Eur J Clin Microbiol Infect Dis (2015) 0.77
The Worsening Profile of Alcoholic Hepatitis in the United States. Alcohol Clin Exp Res (2016) 0.76
Gut microbiome and liver disease. Transl Res (2016) 0.76
No increased risk of herpes zoster found in cirrhotic patients: a nationwide population-based study in Taiwan. PLoS One (2014) 0.75
The Clinical Course of Cirrhosis Patients Hospitalized for Acute Hepatic Deterioration: A Prospective Bicentric Study. Medicine (Baltimore) (2015) 0.75
Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am (2017) 0.75
Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol (2016) 0.75
Practical Concerns and Controversies in the Management of Alcoholic Hepatitis. Gastroenterol Hepatol (N Y) (2016) 0.75
Impact of Hepatic and Extrahepatic Insults on the Outcome of Acute-on-Chronic Liver Failure. J Clin Exp Hepatol (2016) 0.75
Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol (2017) 0.75
The Effect of Adrenal Replacement Therapy on Rates of Fungal Colonization and Mortality in Critically Ill Patients Awaiting Liver Transplantation. J Clin Transl Hepatol (2013) 0.75
Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clin Mol Hepatol (2015) 0.75
Infections in severe alcoholic hepatitis. Ann Gastroenterol (2016) 0.75
Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine (Baltimore) (2017) 0.75
Acute-on-chronic liver failure: recent update. J Biomed Res (2017) 0.75
Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. Dig Dis Sci (2016) 0.75
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform (2008) 71.12
Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep (2007) 11.94
Hospital-acquired infections due to gram-negative bacteria. N Engl J Med (2010) 6.61
Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut (2011) 3.02
Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology (2010) 3.00
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis (2001) 2.76
Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology (2011) 2.39
A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.32
Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol (2011) 2.23
Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.22
Sepsis and endothelial permeability. N Engl J Med (2010) 2.17
Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol (2011) 1.99
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol (2010) 1.63
The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol (2009) 1.57
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology (2012) 1.39
Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol (2010) 1.36
Comparative supragenomic analyses among the pathogens Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae using a modification of the finite supragenome model. BMC Genomics (2011) 1.11
The economic impact of infection control: making the business case for increased infection control resources. Am J Infect Control (2005) 1.08
Infection prevention and comparative effectiveness research. JAMA (2011) 0.89
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med (2013) 5.19
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology (2010) 5.00
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
The Budd-Chiari syndrome. N Engl J Med (2004) 3.95
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
Splanchnic artery aneurysms. Mayo Clin Proc (2007) 2.55
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative. J Clin Oncol (2008) 2.39
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Acute kidney injury in decompensated cirrhosis. Gut (2012) 2.29
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology (2014) 2.27
Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology (2008) 2.26
Hip pain and heart failure: the missing link. Can J Cardiol (2013) 2.26
Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology (2006) 2.25
Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol (2011) 2.23
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol (2013) 2.14
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Mesenteric venous thrombosis. Mayo Clin Proc (2013) 2.09
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Sublingual tissue perfusion improves during emergency treatment of acute decompensated heart failure. Am J Emerg Med (2011) 2.08
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol (2012) 1.98
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Performance standards for therapeutic abdominal paracentesis. Hepatology (2004) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant (2004) 1.87
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology (2012) 1.86
Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl (2007) 1.86
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl (2003) 1.83
Hepatocellular carcinoma after the Fontan procedure. N Engl J Med (2013) 1.81
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology (2006) 1.71
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology (2008) 1.70
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol (2013) 1.66
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology (2003) 1.65
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol (2010) 1.62
Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 1.58
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology (2004) 1.57
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One (2013) 1.51
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50
Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci (2007) 1.50
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49
Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology (2007) 1.48
Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol (2005) 1.47
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41